Immune-checkpoint blockade is able to achieve durable responses in a subset of patients; however, we lack a satisfying comprehension of the underlying mechanisms of anti-CTLA-4-and anti-PD-1-induced tumor rejection. To address these issues, we utilized mass cytometry to comprehensively profile the effects of checkpoint blockade on tumor immune infiltrates in human melanoma and murine tumor models. These analyses reveal a spectrum of tumor-infiltrating T cell populations that are highly similar between tumor models and indicate that checkpoint blockade targets only specific subsets of tumor-infiltrating T cell populations. Anti-PD-1 predominantly induces the expansion of specific tumor-infiltrating exhausted-like CD8 T cell subsets. In contrast, anti-CTLA-4 induces the expansion of an ICOS + Th1-like CD4 effector population in addition to engaging specific subsets of exhaustedlike CD8 T cells. Thus, our findings indicate that anti-CTLA-4 and anti-PD-1 checkpoint-blockadeinduced immune responses are driven by distinct cellular mechanisms.
INTRODUCTION
Immunotherapy is assuming a role as a pillar of cancer treatment, but the remarkable immune-mediated responses are limited to a minority of patients. Immune-checkpoint blockade (ICB) is able to elicit durable responses in a fraction of cancer patients. For example, 22% of advanced-melanoma patients treated with anti-CTLA-4 have durable responses extending beyond 10 years (Hodi et al., 2010; Schadendorf et al., 2015) . Similarly, blockade of the PD-1/PD-L1 signaling axis is also sufficient to induce significant responses in multiple tumor types (Brahmer et al., 2012; Topalian et al., 2012) . Despite such tremendous clinical progress, we still lack a detailed understanding of the fundamental mechanisms that underlie anti-CTLA-4-and anti-PD-1-induced tumor immune rejection, which is necessary for the improvement of current therapies and for the rational design of combination therapy approaches. The aspects of the host immune response and the tumor intrinsic properties that define therapeutic sensitivity to ICB therapy remain to be elucidated (Sharma and Allison, 2015; Topalian et al., 2015) . Despite evidence that tumor properties such as mutational load (Hugo et al., 2016; McGranahan et al., 2016) and genetic lesions (Gao et al., 2016; Spranger et al., 2015; Zaretsky et al., 2016) can influence therapeutic response to ICB, we do not fully understand why different tumor types display such a range of therapeutic sensitivity. Conceptually, such differences could arise because different tumor types elicit fundamentally distinct immune responses or, alternatively, because the magnitude of host immune responses varies between different tumor types.
A critical unresolved question is whether anti-tumor immune responses induced by anti-CTLA-4 and anti-PD-1 antibodies are mediated through distinct, non-redundant mechanisms. A wealth of studies have demonstrated that CTLA-4 and PD-1 attenuate T cell activation through distinct mechanisms (Pardoll, 2012) . CTLA-4 is upregulated immediately following TCR ligation and outcompetes CD28 for B7 ligand binding, thus attenuating positive costimulation by CD28 (Krummel and Allison, 1995; Walunas et al., 1994) . PD-1 is induced later during T cell activation and, upon engagement with PD-L1 or PD-L2, attenuates TCR signaling via recruitment of tyrosine phosphatases (Chemnitz et al., 2004; Freeman et al., 2000; Latchman et al., 2001) . In addition to utilizing distinct molecular mechanisms of action, CTLA-4 and PD-1 attenuate T cell activity through mechanisms that are separated spatially and temporally. Whereas CTLA-4 primarily attenuates T cell activation in the priming phase through cell intrinsic and extrinsic mechanisms, PD-1 primarily attenuates T cell activity in peripheral tissues through cell intrinsic mechanisms (Pardoll, 2012; Walker and Sansom, 2011) . This distinction is highlighted by the fact that the cellular sources of the ligands of PD-1 and CTLA-4 are different and serve different physiological functions. Thus, we hypothesized that anti-CTLA-4-and anti-PD-1-induced anti-tumor immune responses are mediated by distinct cellular mechanisms.
To address this hypothesis, we utilized mass cytometry to comprehensively profile the immune infiltrates of solid tumors following ICB. Mass cytometry allows for the interrogation of more than 40 analytes at single-cell resolution and enables systematic identification of complex cellular populations using high-dimensional analyses (Newell and Cheng, 2016; Tanner et al., 2013) . Mass-cytometry-driven approaches have been utilized to characterize cellular processes including hematopoiesis, immune-cell differentiation, and leukemic disease progression (Bendall et al., 2011; Spitzer and Nolan, 2016) and, more recently, to analyze the immune infiltrates of solid tumors (Chevrier et al., 2017; Lavin et al., 2017; Leelatian et al., 2017; Spitzer et al., 2017) . Here, we leverage mass cytometry to comprehensively characterize the cellular mechanisms of ICB in human melanoma and murine syngeneic transplantable tumor models. Comparisons of murine tumor models indicate that the phenotypes of infiltrating T cell populations and mechanisms of ICB are tumor-type independent. Both anti-PD-1 and anti-CTLA-4 only target a subset of tumor-infiltrating T cell populations, inducing the expansion of exhausted-like CD8 T cells. Notably, anti-CTLA-4 but not anti-PD-1 modulates the CD4 effector compartment, specifically inducing the expansion of an ICOS + Th1-like CD4 effector subset. Together, these pre-clinical and clinical analyses indicate that anti-tumor immune responses induced by CTLA-4 and PD-1 blockade are driven by distinct cellular mechanisms.
RESULTS

Identification of Checkpoint-Blockade-Responsive MC38 Tumor-Infiltrating T Cell Subsets
To identify ICB-responsive tumor-infiltrating T cell populations, we profiled tumors by mass cytometry and utilized a well-validated data-driven unsupervised clustering approach to classify cellular populations (Levine et al., 2015; Melchiotti et al., 2017; Shekhar et al., 2016) . We further validated this approach for quantitative de novo classification of tumor-infiltrating lymphocyte (TIL) populations using spike-in experiments ( Figure S1 ; STAR Methods). To comprehensively characterize tumor-infiltrating T cell populations, we designed a staining panel with 33 surface and 10 intracellular markers. This panel included non-T cell lineage markers (e.g., CD11b, CD11c, CD19), T cell differentiation and activation markers (e.g., PD-1, ICOS, TIM3, KLRG1, CD127), and importantly, T cell lineage transcription factors (e.g., TBET, EOMES, GATA3, BCL6, RORgT, FOXP3) . Using this approach, we analyzed immunogenic MC38 colorectal tumors from mice treated with anti-CTLA-4 or anti-PD-1. To enable analysis of TILs, we empirically defined a tumor inoculation dose and treatment schedule (using standard antibody dosages) such that tumors were not completely rejected at time of analysis despite induction of an effective immune response. Treatment was initiated only after tumors became palpable and thus also more closely reflected the clinical context. We focused our analyses on the T cell compartment given our current understanding of CTLA-4 and PD-1 biology, the design of our staining panel, and analyses of the total CD45 + compartment ( Figure S1 ).
Analysis of the T cell compartment revealed dramatic population shifts in response to anti-CTLA-4 and anti-PD-1 (Figures 1A and 1B) . These observations are consistent with an increase in CD8/T reg ratio following both treatments, as determined by manual gating analyses and reflect the induction of an effective immune response by ICB ( Figure 1C ).
To gain a more in-depth understanding of the mechanisms that underlie ICB, we generated a high-resolution map of phenotypically defined tumor-infiltrating T cell populations using unsupervised clustering. 15 distinct MC38 tumor-infiltrating T cell clusters of >0.5% relative frequency were identified, including 5 CD8, 2 T reg , and 2 CD4 effector clusters ( Figures  1D-1F ). This approach focused specifically on tumor-infiltrating populations, and thus many canonical T cell subsets present in other tissues would not be expected present (e.g., naive); as such, this represents an extensive catalog of infiltrating T cell subsets. Notably, ICB did not modulate the frequency of any NKT, gd T cell, or low frequency (<0.5%) clusters. Thus, we focused our analyses on CD4 and CD8 T cell subsets, which displayed a range of activation and exhaustion phenotypes ( Figure 1G ). Both anti-CTLA-4 and anti-PD-1 treatment led to an expansion of CD8 T cells; however, not all CD8 T cell subsets expanded following ICB. Surprisingly, a phenotypically exhausted PD-1 hi TIM3
+ population expanded the most among CD8 populations ( Figure 1F ). To address whether T cell expansion results from increased proliferation or infiltration, we assessed short-term incorporation of 5-iodo-deoxyuridine (IdU). ICB-responsive CD8 clusters incorporated IdU, suggesting that these cells are proliferating within the tumor microenvironment (TME) ( Figure S1I ). Given the timing of IdU treatment and retention of IdU in daughter cells, this approach may detect extratumoral-blasting T cells that subsequently infiltrate the tumor, in addition to cells proliferating within the TME. Nonetheless, these observations indicate that ICB-sensitive T cells retain proliferative capacity even after multiple rounds of (B) Overlaid t-SNE plot displaying equal number of events from each treatment group (control, blue; anti-CTLA-4, green; anti-PD-1, red).
(C) Plot of CD8/T reg ratios displayed on a per-mouse basis with mean ± SD (*p < 0.05, unpaired t test).
(D) t-SNE plot of MC38 infiltrating T cells overlaid with color-coded clusters.
(E) t-SNE plot of infiltrating T cells overlaid with the expression of selected markers.
(F) Frequency of T cell clusters displayed on a per-mouse basis with mean ± SD (*, control versus anti-CTLA-4; #, control versus anti-PD-1; p < 0.05, Dunnett's multiple comparison). T cell compartments are denoted including CD8, T reg , and CD4 effector (CD4 eff ).
(G) Heatmap displaying normalized marker expression of each T cell cluster.
Representative data from three independent experiments is shown. See also Figure S1 and STAR Methods. therapy and that ICB leads to the expansion of only specific intratumoral T cell subsets. We next assessed the effect of ICB on CD4 T cell populations. Within the T reg compartment, two clusters were identified that are largely distinguished by KLRG1 expression ( Figure 1G ). Relative T reg frequency decreased following both anti-PD-1 and anti-CTLA-4, consistent with a shift between effector and regulatory T cell populations (Quezada et al., 2006) . The magnitude of this decrease was greater following CTLA-4 blockade, consistent with findings that treatment with anti-CTLA-4 leads to intratumoral T reg depletion in murine tumor models (Selby et al., 2013; Simpson et al., 2013) . Two CD4 effector T cell subsets were identified in the TME, and both display an activated phenotype but differ in their expression of key markers including PD-1 and TBET ( Figure 1G ). Most notably, treatment with anti-CTLA-4 but not anti-PD-1 was associated with a significant expansion of a TBET + Th1-like CD4 effector subset ( Figure 1F ).
This population was proliferative but to a lesser degree than other clusters ( Figure S1I ). We denote this subset as distinct from canonical Th1 cells because of expression of PD-1 and ICOS, which are defining characteristics of T follicular helper (TFH) cells, despite expression of TBET but not BCL6 (Th1-and TFH-lineage transcription factors, respectively). Neither therapy led to an expansion of un-skewed activated CD4 effectors. These observations suggest that specific T cell subsets are targeted by ICB and that anti-CTLA-4 leads to expansion of CD4 effector T cells.
Identification of Checkpoint-Blockade-Responsive B16BL6 Tumor-Infiltrating T Cell Subsets We then sought to determine whether these findings reflect a generalizable mechanism of ICB responses. For this purpose, we performed similar experiments in the poorly immunogenic B16BL6 melanoma model to contrast the relatively high immunogenicity of MC38, allowing us to distinguish ICB response phenomena from tumor-type-specific observations. Due to low baseline T cell tumor infiltration and the lack of response to anti-CTLA-4 monotherapy (van Elsas et al., 1999) , we treated mice with a single dose of the GVAX tumor vaccine in order to boost overall T cell infiltration. As in the MC38 system, we empirically defined the B16BL6 tumor inoculate and treatment schedule (using standard antibody dosages) such that tumors were not completely rejected at time of analysis despite induction of an effective immune response. Analysis of CD45 + TILs revealed significant therapy-induced changes in immune composition ( Figure S2 ). We focused our analyses on the T cell compartment to identify ICB-responsive T cell populations.
Reflective of induction of an effective immune response, significant shifts in T cell populations in the TME were observed following treatment with anti-CTLA-4 and anti-PD-1 ( Figures  2A and 2B) , which mirrored an increase in CD8/T reg ratio as determined by manual gating ( Figure 2C ). Clustering identified 13 clusters of frequency greater than 0.5% including 5 CD8, 3 T reg , 2 CD4 effector, NKT, and gd T cell clusters ( Figures 2D  and 2E ). ICB did not affect the frequencies of any NKT, gd T cell, or low-frequency subsets. Remarkably, despite analysis of a different tumor type, time point of tumor progression, and the addition of a GM-CSF-expressing tumor vaccine, the T cell clusters identified in B16BL6 tumors were nearly identical to those identified in MC38 tumors. Of the five identified CD8 clusters, only a subset were responsive to ICB with PD-1 + TIM3 + exhausted CD8 T cells expanding the most (Figures 2E and 2F ). Of the three T reg subsets identified, two contracted significantly following ICB. These populations differ primarily in their expression of KLRG1, with KLRG1 + T reg decreasing in relative frequency most dramatically. Of the two CD4 effector populations identified, both displayed an activated CD44 + CD62L lo phenotype but were distinguished by expression of PD-1, CD127, and TBET ( Figure 2F ). Notably, the frequency of TBET + Th1-like CD4 effector T cells increased following anti-CTLA-4 but not anti-PD-1 ( Figure 2E ). Thus, as observed in MC38 tumors, both anti-CTLA-4 and anti-PD-1 induce the expansion of specific T cell subsets and differentially affect CD4 effector T cells.
MC38 and B16BL6 Tumor-Infiltrating T Cell Populations Are Fundamentally Similar
The remarkable similarity in T cell populations identified by unsupervised clustering in MC38 and B16BL6 tumors suggests that the mechanisms governing responses to ICB are tumor-type independent. Conceptually, this implies that the same types of T cells are involved in anti-tumor T cell responses to different tumor types, at least in the context of transplantable murine tumor models. To explicitly address this possibility, we analyzed the multivariate profiles of infiltrating T cell populations from MC38 and B16BL6 tumors simultaneously in order to identify any significant associations between T cell phenotype and tumor type. Projecting these phenotypes into the coordinate axes defined by their principal components, we asked whether the distributions along each component differed significantly between MC38-and B16BL6-derived T cell populations (STAR methods). In other words, we asked whether any of the phenotypic variance among all T cell populations observed in all treatments (independent of frequency) was attributable to the tumormodel source. Representative data from three independent experiments is shown. See also Figure S2 .
Comparison along each principal-component axis revealed that MC38 and B16BL6 tumor-infiltrating T cell subpopulations are phenotypically indistinguishable (Figure 3 ; Table  S1A ). The distribution of T cell subpopulations derived from MC38 and B16BL6 tumors did not differ along 38 of 39 principal components, which together explain 95% of the variance of the data (Table S1A ). In the one case where a significant difference was detected (PC6), the discrepancy was attributable to contaminating CD19 + subpopulations in several MC38 samples and likely represents a technical artifact rather than a biological effect. This analysis indicates that there is no association between tumor model and the vast majority of phenotypic variance among the T cells identified in these models. This observation is confirmed visually by the overlap of MC38-and B16BL6-derived T cell populations plotted on biaxial pairs of the largest principal-component projections ( Figure 3) . Thus, the multivariate phenotypes of T cell subsets from MC38 and B16BL6 tumors are quantitatively similar. This finding is striking given the use of the GVAX tumor vaccine only with the B16BL6 model and the difference in immunogenicity of these models. Consistent with MC38 being highly immunogenic and B16BL6 being poorly immunogenic, MC38 has more than 2-fold more nonsynonymous single-nucleotide variants (SNV) than B16BL6 (2,327 and 1,107, respectively; Table S1B ). These data indicate that the types of T cells that infiltrate transplantable murine tumors are tumor-type independent and suggest that differences in immunogenicity between tumor types arise due to tumor intrinsic properties that modulate the magnitude (e.g., subset frequency), but not type, of anti-tumor T cell responses. Combined with the observation that similar T cell subsets are regulated in response to ICB in both tumor models, this suggests that the cellular mechanisms of CTLA-4 and PD-1 blockade are tumor-type independent.
Identification of B16BL6-Infiltrating T Cell Populations that Correlate with Tumor Growth
We then sought to identify T cell populations whose frequencies correlate with tumor growth to gain insight into their functional relevance. For this purpose, we leveraged our B16BL6 datasets and combined three independent biological replicate cohorts, which together displayed a robust response to ICB (Figures 4A and 4B) . Using a metaclustering approach, in which populations first identified at the individual mouse level using PhenoGraph are then allowed to merge across cohorts (STAR Methods), 14 T cell populations were identified. The phenotypes and responses of these subsets to ICB were consistent with findings from single cohort analyses. Because ICB only modulated the frequencies of CD4 and CD8 T cell subsets, we focused our analyses on the 10 metaclusters within these compartments ( Figures 4C, 4D , and S3). Expectedly, the frequency of major T reg subsets correlated positively with tumor growth ( Figures  4E and S3 ). The two major T reg populations are primarily distinguished by KLRG1 expression, with the frequency of KLRG1 + T reg (MC4) correlating more strongly with tumor growth than KLRG1 À T reg (MC0) or manually gated T reg ( Figure S3 ; Tables   S2A and S2B ). Whether this difference reflects differences in functionality or response to ICB is unclear; however, both subsets significantly correlated with tumor growth, suggesting that both retain suppressive activity. Surprisingly, the frequency of only two of the four tumorinfiltrating CD8 T cell subsets negatively correlated with tumor growth ( Figure 4E ). These populations displayed an activated phenotype and increased frequencies following anti-CTLA-4 and anti-PD1 treatment ( Figures 4C and 4D (Table  S2A ). Thus, subtle multivariate phenotypic differences between metaclusters 2, 10, and 13 distinguish T cell populations that significantly differ in their correlation with tumor growth, which likely reflects functional differences between these populations. Moreover, these data suggest that fully exhausted non-terminally differentiated T cells (MC13) may not contribute significantly to tumor rejection in the context of ICB, at least during later stages of response. In contrast, less-exhausted non-terminally differentiated (MC2) and fully exhausted terminally differentiated (MC10) appear to provide the bulk of the functional antitumor T cell response. Unexpectedly, the frequency of a non-proliferative CD44
positively correlated with tumor growth ( Figure 4E ; Table S2A ). This population may be tumor-irrelevant central memory CD8 T cells, raising the possibility that infiltration of antigen-irrelevant CD8 T cells is not only ineffective but may in fact dampen the anti-tumor immune response. In terms of the proliferative capacity of effective CD8 T cell subsets, MC10 incorporated IdU at almost four times the rate of MC2 ( Figure S3C ). In contrast, despite being highly proliferative, the frequency of MC13 does not correlate with tumor growth. This suggests that high proliferative capacity of CD8 T cells in the TME during later stages of responses to ICB is neither necessary nor sufficient for effective anti-tumor responses. Whether effective CD8 T cell subsets of low (MC2)-and high (MC10)-proliferative capacity contribute through distinct functions remains unclear. The two CD4 effector T cell metaclusters identified include a PD-1 hi TBET + Th1-like subset (MC3) and a PD-1 lo CD44 int C-D127 int subset (MC5). Only the frequency of MC3 negatively correlated with tumor growth ( Figure 4E ; Table S2A ). Notably, this correlation is driven by the specific expansion of this population following anti-CTLA-4 treatment. Interestingly, the Th1-like population displayed a low proliferation rate in both B16BL6 and MC38 tumor models ( Figures S1 and S3 ), raising the possibility that modulation of this population by anti-CTLA-4 may primarily occur at earlier time points or in secondary lymphoid organs. Together, these data indicate that only specific populations of tumor-infiltrating CD4 and CD8 T cells mediate responses to ICB and suggest that the quantification of these phenotypically defined T cell subsets will provide improved predictive value compared to assessment of bulk compartments (e.g., CD8 T cells). These findings reinforce the notion that data-driven multivariate analyses enable unbiased comprehensive cellular classification and robust de novo discovery of biologically relevant T cell clusters MC38-derived B16BL6-derived Figure 3 . B16BL6 and MC38 Tumor-Infiltrating T Cell Populations Are Quantitatively Similar (A) PCA was applied to T cell clusters identified on a per-mouse basis from MC38 and B16BL6 mass cytometry datasets. Projections of MC38 and B16BL6 infiltrating T cell clusters on to the first six principal components (PC), which together account for 78% of the phenotypic variance, are displayed in a pair-wise fashion (MC38, green; B16BL6, blue). Univariate distributions of T cell clusters along each of the first six principal components are displayed along the diagonal. The Kolmogorov-Smirnov test was applied to test whether distributions of MC38-and B16BL6-derived T cell clusters along each PC are different (n.s., not significant). See also Table S1 . populations. It is important to note that while we ascribe key phenotypic features to identified clusters ( Figure 4 ; Table S2A ), quantitative multivariate analyses provide vastly improved subset assignment compared to manual gating. We sought to determine whether the insights provided by high-dimensional analyses would enable approximation of these subsets by manual gating. Using a limited number of key parameters derived from multivariate analyses, manual gating is able to discriminate relevant T cell subsets, albeit with significantly reduced fidelity (Figure S3E ; Table S2B ). Consistent with the importance of lineage transcription factors for robust subset identification, expression of TBET but not individual surface markers was sufficient to identify CD4 effector subpopulations that significantly negatively correlate with tumor growth. Figure S4 ). Of the top 15 cellular pathways regulated by each treatment, only 3 were shared. Mitochondrial and oxidative phosphorylation pathways were among the most significantly modulated by anti-PD-1, consistent with findings that these pathways can restrict T cell activity in the TME (Bengsch et al., 2016; Gubin et al., 2014) . CTLA-4 blockade led to an engagement of largely distinct pathways, which included pathways involved in cell-cycle regulation. These observations indicate that anti-CTLA-4 and anti-PD-1 induce differential transcription effects in tumor-infiltrating CD4 T cells and support the paradigm that these therapies act through distinct mechanisms.
Differential Transcriptional Regulation in
Anti-CTLA-4 and Anti-PD-1 Therapies Modulate Specific T Cell Populations in Human Melanoma
Finally, we sought to determine whether distinct cellular mechanisms also underlie anti-CTLA-4 and anti-PD-1 tumor rejection in humans. Using a similarly designed human T cell mass cytometry panel, we analyzed surgically resected melanoma tumors from patients being treated with ipilimumab (ipi), anti-PD-1 (nivolumab, nivo; or pembrolizumab, pembro), or ipi plus nivo (Table  S3 ). This approach enables direct interrogation of tumor-infiltrating T cell populations that may not be fully represented in peripheral blood. t-SNE analysis revealed striking differences between normal donor blood and tumor-infiltrating T cells, as well as treatment-specific effects (Figures 5A-5C and S5). To more deeply interrogate the effects of anti-CTLA-4 therapy, we compared samples from patients being treated with ipi (alone or in combination with nivo) or anti-PD-1 monotherapy. This approach enabled more robust statistical analyses given the rarity of ipi monotherapy tumor samples in the current landscape of standard of care therapy for patients with metastatic melanoma. Unsupervised clustering of tumor and normal donor blood samples identified 19 distinct T cell subsets, including 5 CD8 and 11 CD4 clusters (Figures 5D and 5E; STAR Methods). The increased number of T cell subsets compared to our murine TIL data likely reflects the identification of canonical subsets in blood that are not present in tumors and as such would be absent from our preclinical analyses. Consistent with this notion, naive T cell subsets were specific to blood, while many of the T cell subsets were observed at similar frequencies in normal donor blood and tumors. Surprisingly, of the 19 T cell subsets identified, only 2 were significantly expanded in ICB-treated tumors compared to normal donor blood. Although most melanoma-infiltrating T cell subsets were actively proliferating, only clusters 1 and 3 significantly expanded, suggesting that they are functionally distinguished by as yet unidentified mechanisms ( Figure S5D Notably, the only ICB-treatment-specific effect observed was an increased frequency of Th1-like T cells in melanomas treated with anti-CTLA-4 compared to those treated with anti-PD-1 (Figure 5D , cluster 3). Thus, remarkably, despite the presence of confounding variables (e.g., diverse treatment histories) and small sample size, these analyses suggest that anti-CTLA-4 and anti-PD-1 therapies modulate only specific tumor-infiltrating T cell subsets and that anti-CTLA-4 induces a more robust CD4 effector response-observations consistent with our preclinical findings. Future studies are needed to validate these findings in a larger patient cohort and to determine whether the discrepancy in the number of ICB-responsive CD8 T cell subsets in mouse and human tumors reflects a difference in underlying biology or rather a technical aspect of our analyses. In both mouse and human, the CD4 effector response is defined by expansion of an ICOS + TBET + Th1-like subset. Notably, despite See also Figure S3 and Table S2 . qualitative (e.g., CD44 versus CD45RO) and quantitative (e.g., levels of ICOS and PD-1) differences in phenotypic profiles of T cells infiltrating human and murine tumors, unsupervised clustering enabled robust detection of biologically analogous populations ( Figures S5E and S5F ). Together, these data indicate that the cellular mechanisms of CTLA-4 and PD-1 blockade are distinct and that the hallmarks of these mechanisms are largely conserved between mouse and human.
DISCUSSION
Here, we systematically classify tumor-infiltrating T cells from murine tumor models and human melanomas in the context of ICB using mass cytometry and unsupervised analyses. These studies provide insight into several key concepts: (1) ICB only induces the expansion of specific tumor-infiltrating T cell subsets, (2) PD-1 blockade primarily induces expansion of exhausted-like tumor-infiltrating CD8 T cells, (3) CTLA-4 blockade induces expansion of ICOS + Th1-like CD4 effector as well as exhausted-like CD8 T cells, (4) the frequency of only specific tumor-infiltrating CD4 and CD8 T cell populations correlates with tumor growth, and (5) the phenotypes of tumor-infiltrating T cell subsets in different transplantable murine tumor models are fundamentally similar. Together, these observations indicate that anti-CTLA-4-and anti-PD-1-induced anti-tumor responses are driven by distinct cellular mechanisms, primarily differing on the expansion of the CD4 effector compartment induced by anti-CTLA-4. Given that we profiled anti-tumor immune responses in the context of partial regression by design, it remains to be determined whether the same mechanisms mediate complete tumor rejection in the context of resolution of antigen burden. The similarity of findings in the MC38 and B16BL6 systems despite analyses of different time points (2 and 10 days after treatment, respectively) suggests that these mechanisms persist and may be independent of the phase of tumor rejection. Our findings are consistent with clinical observations that increased CD8, but not CD4, T cell activity is associated with anti-PD-1 therapy in melanoma (Daud et al., 2016) and also consistent with the fundamental understanding that PD-1 and CTLA-4 attenuate T cell activation through distinct molecular and cellular mechanisms. It is likely that dual engagement of these distinct cellular mechanisms underlies, at least in part, the enhanced efficacy of combination anti-CTLA-4 and anti-PD-1 therapy that has been observed in preclinical and clinical contexts (Curran et al., 2010; Wolchok et al., 2013) .
Additional mechanistic investigation of anti-CTLA-4 and anti-PD-1 is also warranted. For example, the necessity and sufficiency of specific ICB-responsive tumor-infiltrating T cell subsets identified in our study remains to be definitively tested. Furthermore, recent studies have shown that anti-PD-1 therapy leads to a dynamic expansion of proliferating PD-1 + CD8 T cells in peripheral blood of melanoma and lung cancer patients (Huang et al., 2017; Kamphorst et al., 2017) . Whether expansion of ICB-responsive exhausted-like CD8 T cells is driven by therapeutic engagement of peripheral or tumor-infiltrating populations is unknown. Furthermore, the degree to which anti-tumor T cell subsets are equally represented in tumor and peripheral blood remains unclear. Analyses of paired tumor and blood samples from patients being treated with ICB therapy may provide critical insight into these issues. Examination of additional parameters, such as costimulatory molecules, may offer additional clarity by providing an even finer resolution catalog of T cell subsets, as in recent analyses of renal cell carcinoma (Chevrier et al., 2017) .
It remains unclear what functionally distinguishes ICB-responsive and nonresponsive CD8 T cell populations. ICB-responsive subsets may represent the bulk of tumor-antigen specific T cells or, alternatively, represent a functionally distinct subset thereof. Distinguishing between these possibilities may inform the development of therapeutic strategies. Likewise, future studies are required to determine whether ICB-responsive CD8 T cell subsets are functionally as well as phenotypically exhausted and, moreover, whether they are functionally distinct from each other. The maintenance of PD-1 on responsive CD8 T cells despite prolonged anti-PD-1 therapy suggests that PD-1 blockade is sufficient to reinvigorate these populations but not to reprogram them into a non-exhausted state, consistent with epigenetic regulation (Pauken et al., 2016) .
Although our findings indicate that CTLA-4 blockade induces an expansion of tumor-infiltrating Th1-like CD4 T cells, the definitive source (anatomical and temporal) and precise function of this expansion remain open questions. It is possible that expansion of specific tumor-infiltrating T cell subsets in response to ICB results from engagement of distinct progenitor populations in secondary lymphoid organs, analogous to findings in viral models (Im et al., 2016) . With respect to function, it is tempting to speculate that expansion of Th1-like CD4 effectors by anti-CTLA-4 improves anti-tumor responses by enhancing CD8 infiltration, cytolytic CD8 activity, and T cell memory formation. Addressing these possibilities is of great interest given that expansion of ICOS + CD4 T cells following ipi treatment has been observed in multiple tumor types (Chaput et al., 2017; Chen et al., 2009; Liakou et al., 2008) , that expansion of ICOS + CD4 T cells is associated with overall survival following ipi therapy (Carthon et al., 2010) , and that genetic loss of Icos attenuates the efficacy of anti-CTLA-4 in preclinical tumor models (Fan See also Figure S5 and Table S3. et al., 2014). Our findings suggest that expansion of the CD4 effector compartment by anti-CTLA-4 differentiates its mechanism of action from that of PD-1 blockade. Such insights will inform the rational design of combinatorial approaches, particularly given the fundamental understanding that CD4 help is critical for the development of robust T cell responses, as well as recent findings that CD4 T cells are critical for effective immunotherapy (Spitzer et al., 2017 ).
In conclusion, we comprehensively profiled T cells in preclinical and clinical tumor samples using a mass-cytometry-based systems approach. We identify specific tumor-infiltrating T cell populations that expand in response to ICB and demonstrate that anti-PD-1 and anti-CTLA-4 operate through distinct cellular mechanisms. These findings highlight the utility of unsupervised systems-based analyses for in-depth mechanistic investigation.
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EXPERIMENTAL MODELS AND SUBJECT DETAILS
Cell lines B16BL6 and B16BL6 GVAX murine melanoma cells were cultured in RPMI-1640 supplemented with 10% FBS, sodium pyruvate, 0.1% b-ME, and P/S as previously described (Quezada et al., 2006; van Elsas et al., 1999) . B16BL6 was originally obtained from I. Fidler (MD Anderson Cancer Center) and the GM-CSF producing B16BL6 GVAX cell line was produced by retroviral transduction as previously described (van Elsas et al., 1999) . MC38 murine colon carcinoma cells were originally obtained from N. Restifo (National Cancer Institute) and cultured in DMEM supplemented with 10% FBS and P/S as previously described (van Elsas et al., 1999) . MC38 was originally derived from a female C57BL6 mouse. Cell lines were periodically tested for mycobacterium contamination. Cell lines were analyzed using whole-exome sequencing (WES) but have not been authenticated further by other methods. In vivo murine tumor experiments 7-week-old female C57BL/6J mice purchased from The Jackson Laboratory were used for B16BL6 and MC38 tumor experiments. Mice were co-housed and allowed to acclimate to the housing facility for at least 1 week. Mice were randomized prior to the first treatment of checkpoint blockade antibodies. In all experiments polyclonal hamster IgG (BioXcell) and anti-CTLA-4 (clone, 9H10, BioXcell), were administered using doses of 200 mg for the initial injection and 100 mg for subsequent injections. Anti-PD-1 (clone, RMP1-14, BioXcell) was administered using doses of 250 mg. 100 mL of 5mg/ml 5-iodo-deoxyuridine (IdU; Sigma-Aldrich) in PBS was administered by intraperitoneal (i.p.) injection 16-18 hours prior to sacrifice in order to assay cell cycle (Behbehani et al., 2012) . Tumors were measured by caliper 2-3 times per week and tumor volume calculated as length x width x height. At time of sacrifice for analysis mice were euthanized using CO 2 and subsequent cervical dislocation.
Human subjects A cohort of 7 patients with metastatic melanoma was included in this study. These patients were treated at The University of Texas Table S3 . Protected health information (PHI) is protected under the UT MDACC PHI policy #ADM0396, as such patient age and gender are not disclosed. At the time of sample acquisition, 1 patient was receiving treatment with CTLA-4 blockade, 3 with PD-1 blockade, and 3 with combined CTLA-4 and PD-1 blockade. Notably, 3 patients received therapy on neoadjuvant protocols. Clinical response was defined using objective radiographic criteria per RECIST 1.1 comparing baseline imaging with restaging imaging at standard-of-care time points. For patients treated with neoadjuvant intent, restaging imaging was performed immediately prior to the planned surgery date, being 8-10 weeks after initiation of therapy.
Fresh melanoma tumors were manually minced prior to enzymatic digestion with 2 mg/mL collagenase A (Roche, Cat. No. 11-088-793-001) and 40 units/mL DNase-I (Sigma-Aldrich, Cat. No. D5025) in DMEM and incubated with agitation at 37 C for 60 min. Following incubation, digests were passed through a 70 mm filter to remove residual particulates. Cells were then pelleted (centrifugation at 600 g for 5 min), washed in PBS, counted using a Trypan Blue exclusion viability dye, and re-pelleted prior to final resuspension at approximately 1-5 million live cells/mL in cell culture freezing media comprised of 90% FBS and 10% DMSO (Sigma-Aldrich, Cat. No. D2650). Samples immediately underwent controlled freezing (CoolCell LX) to À80 C before being moved into long-term liquid nitrogen storage.
Normal donor peripheral mononuclear blood cells (PBMC) were isolated by Ficoll density gradient centrifugation of heparinized whole blood obtained from the Gulf Coast Blood Bank (Ficoll 1.077 Accu-Prep Lymphocytes, Axis-Shield #1114547). Isolated PBMC were cryopreserved in 20% DMSO 80% AB serum (Sigma-Aldrich, H4522) and thawed prior to mass cytometry analysis.
METHOD DETAILS
Mass cytometry antibodies
Metal conjugated antibodies were purchased from Fluidigm or conjugated to unlabeled antibodies in house. All non-platinum conjugations were performed using X8 polymer as per manufacturer's protocol (Fluidigm) and were performed at 100 mg or 200 mg scale. 139 La was sourced from either from Fluidigm or Sigma-Aldrich. Monoisotopic platinum antibody conjugations were performed using a protocol adapted from Mei and colleagues (Mei et al., 2016) . Briefly, up to 100 mg of antibody was washed in R buffer (Fluidigm) on a 50kDa spin filter column (EMD Millipore) and reduced in 4mM TCEP (Sigma-Aldrich) in R buffer for 30 min at 37 C. All wash steps included a 7 min centrifugation at 12,000 g with subsequent resuspension in the appropriate buffer. The antibody was then washed twice with C buffer (Fluidigm) and incubated with 400 mL of 100 mM monoisotopic cisplatin (Fluidigm) in C buffer. Antibodies were then washed four times with W buffer (Fluidigm). All in-house conjugated antibodies were diluted to 0.5mg/ml in antibody stabilizer supplemented with 0.05% sodium azide (Candor Biosciences). Appropriate antibody dilution in the context of each panel was determined by serial dilution staining experiments with replicates of relevant biological samples (e.g., murine tumor, human PBMC, human TILs) to minimize background and optimize detection of positively expressing populations. Mass cytometry staining panels are detailed in Table S4A -S4C. Surface and intracellular staining cocktail master mixes were prepared prior to each experiment.
Mass cytometry analysis of murine tumors
Tumors were dissected, manually dissociated, and digested enzymatically with Liberase TL (Roche) and DNase I (Roche) in RPMI-1640 for 30 min at 37 C with intermittent inversion. Digested tumors were then mashed through 70 mm filters into RPMI-1640 supplemented with 10% FBS, sodium pyruvate, b-ME, and P/S. Single cell suspensions were then purified on a Histopaque-1119 (Sigma-Aldrich) discontinuous gradient centrifuged at 2000rpm for 20 min at room temperature. Live cells were then washed twice with FACS buffer and total cell concentration determined using an A2000 Cellometer (Nexcelom). 3x10 6 or fewer cells per tumor were then incubated with 2% of each bovine, murine, rat, hamster, and rabbit serum PBS with 25 mg/mL 2.4G2 antibody at 4 C for 10 min prior to surface staining with an antibody cocktail at 4 C for 30 min in a 50 mL volume. Cells were incubated with 2.5 mM 194Pt monoisotopic cisplatin (Fluidigm) at 4 C for 1 min. Cells were washed twice with FACS buffer and barcoded using palladium metal barcoding reagents according to manufacturer's protocol (Fluidigm). Cells were then fixed and permeabilized using the Foxp3 fix and permeabilization kit according to manufacturer's protocol (eBioscience). Cells were subsequently stained with an intracellular stain antibody cocktail for 30 min at room temperature. Cells were then washed twice with Foxp3 permeabilization buffer, twice with FACS buffer, and incubated overnight in 1.6% PFA PBS with 100nM Iridium nucleic acid intercalator (Fluidigm). Cells were then washed twice with 0.5% BSA PBS, filtered, and washed twice with 0.1% BSA water prior to analysis. Samples were then analyzed using a CyTOF2 or Helios mass cytometer using the Helios 6.5.358 acquisition software (Fluidigm). The mass cytometry staining panel described in Table S4B was used for analysis of MC38 and B16BL6 TILs in checkpoint blockade experiments.
Synthetic tumor spike-in experiments 4x10
5 MC38 tumor cells were injected subcutaneously on the flank and mice sacrificed on day 14. Live, single cell suspensions from individual tumors were isolated as described above. Single cell suspensions of peripheral lymph node cells from pooled inguinal, axillary, and brachial lymph nodes were isolated from naive CD45.1 + congenic mice. Total cell concentration determined using a Cellometer (Nexcelom). Total cell fractions from individual tumor samples were spiked with naive CD45.1 + lymphocytes to final concentrations of 0%, 1%, 5%, and 20% total cell number. A total of 10 6 cells per sample were stained using the panel described in Table S4A . Samples were then incubated with 2% of each bovine, murine, rat, hamster, and rabbit serum PBS with 25 mg/mL 2.4G2 antibody at 4 C for 10 min prior to surface staining with an antibody cocktail at 4 C for 30 min in a 50 mL volume. Cells were incubated with 2.5 mM 194Pt monoisotopic cisplatin at 4 C for 1 min. Cells were washed twice with FACS buffer and barcoded using palladium metal barcoding reagents according to manufacturer's protocol (Fluidigm). Cells were fixed in 1.6% PFA in PBS at 4 C for 20 min and then incubated overnight in 1.6% PFA PBS with 100nM Iridium nucleic acid intercalator (Fluidigm). Cells were then washed twice with 0.5% BSA PBS, filtered, and washed twice with 0.1% BSA water prior to analysis. Samples were then analyzed using a CyTOF2 or Helios mass cytometer using the Helios 6.5.358 acquisition software (Fluidigm). Downstream dimension reduction and clustering analyses of these datasets were performed agnostic to the expression of the congenic marker CD45.1. In order to guide interpretation of future experiments we sought to determine both the false positive rate and sensitivity of cluster identification. Based on the known population frequency extrapolated from the spike-in fraction, we were able to identify unique clusters of less than 1% frequency. False positive identification rate was between 0.1% and 1%. These are conservative estimates and this approach is likely considerably more sensitive. Based on these findings a cutoff frequency of 0.5% was applied to preclinical murine tumor model experiments described in this study.
Mass cytometry analysis of human melanoma tumors
Cryopreserved melanoma tumor digests (see Experimental Models and Subjects section for detailed protocol) were thawed and mashed through 70 mm filters into RPMI-1640 with 10% FBS and P/S. Single cell suspensions were then purified on a Histopaque-1119 (Sigma-Aldrich) discontinuous gradient centrifuged at 2000rpm for 20 min at room temperature. Live cells were then washed twice with FACS buffer and total cell concentration determined using an A2000 Cellometer (Nexcelom). Up to 3 staining reactions of a maximum of 2.5x10 6 cells per tumor sample were analyzed, each barcoded separately (only samples from patients 120 and 170 had sufficient cellular content for multiple staining reactions; see analysis section). 1.5x10 6 PBMCs were analyzed per normal donor blood sample. All samples were then incubated with 2% of each bovine, murine, rat, hamster, and rabbit serum PBS with human TruStain FcX (Biolegend, 422302) at 4 C for 15 min. Samples were then processed for surface and intracellular staining with the panel described in Table S4C using a similar protocol as described for processing and staining murine tumor samples. Samples were analyzed using a Helios mass cytometer (Fluidigm).
RNA-seq of murine tumor infiltrating T cells C57BL/6J mice were subcutaneously injected with 4x10 5 MC38 tumor cells. Mice were treated with checkpoint blockade antibodies on days 5, 8, and 11 and sacrificed 12 days post tumor inoculation. Tumors were dissociated and single cell suspensions were isolated from individual mice using a similar protocol as described for mass cytometry analyses. Single cell suspensions were then incubated with a surface staining cocktail of fluorescently conjugated antibodies, which included CD45.2 e450 (clone 104, eBioscience, 48-0454-82), CD3ε PerCP Cy5.5 (clone 145-2C11, eBioscience, 45-0031-82), CD4 PE (clone RM4-5, eBioscience, 12-0042-85), CD8 APC (clone eBioscience, , ICOS FITC (clone 7E.17G9, eBioscience, , as well as live/dead discrimination viability dye e780 (eBioscience, . Activated tumor infiltrating ICOS + CD4 T cells were sorted directly into RLT buffer using a FACS AriaFusion cell sorter (BD). Lysates were homogenized using a QiaShredder and RNA extracted using RNeasy Micro kit (QIAGEN) according to the manufacturer's protocol. Due to low RNA yield from sorted tumor infiltrating T cell populations from individual mice, libraries were prepared using Ovation single-cell RNaseq system (NuGEN). Indexed libraries were analyzed by 76-nucleotide paired end sequencing on a HiSeq 4000 system (Illumina). A notable caveat of these experiments is that samples included both CD4 effector and T reg populations; however, the regulation of pathways largely unrelated to canonical T reg supports the notion that the transcriptional changes observed are due to differential expression profiles rather than changes in T reg frequency.
Whole-exome sequencing of murine cell lines Genomic DNA was extracted from tumor cell line pellets using DNeasy Blood and Tissue kit (QIAGEN). Samples libraries were prepared using NimbleGen SeqCap EZ Developer library murine whole exome capture kit (Roche, design: 110624_MM9_Exome L2R_D02_EZ, catalog # 06471706001). Indexed sample libraries were sequenced by 76-nucleotide pair end sequencing on a HiSeq2000 sequencer (Illumina).
QUANTIFICATION AND STATISTICAL ANALYSIS
Analysis of murine tumor mass cytometry datasets Mass cytometry data were normalized to EQ 4-element bead signal (Lot P15K0802, Passport EQ 4_P13H2302) in 100 s interval windows using normalization software version 2 (Fluidigm). Mass tag barcodes were resolved with a doublet filtering scheme using Debarcoder (Fluidigm). Samples were manually gated in FlowJo by event length, live/dead discrimination, and by the desired expression markers (e.g., CD45, CD3ε, CD4, CD8) for each particular analysis. Data were then exported for downstream analysis and arcsinh transformed using a coefficient of 4. For most downstream analyses the individual sample data were subsampled to 10 4 to 3x10 4 events. Samples with less than 1000 events in the final gate (e.g., T cells) were excluded due to insufficient events for accurate clustering and frequency calculations. We set this cut-off based on the reasoning that 1000 events would be sufficient for phenotypic clustering and dimension reduction analyses in the context of many total events. Samples censored for this reason were also omitted from growth kinetic, final tumor volume, and manual gated frequency analyses. t-Distributed Stochastic Neighbor Embedding (t-SNE) dimension reduction and PhenoGraph clustering analyses were performed using the tool Cyt run in MATLAB or in Python (Amir et al., 2013; Levine et al., 2015) . t-SNE and PhenoGraph analyses were performed using all markers not utilized for manually gating, except where exclusion of additional markers is otherwise noted (e.g., IdU, CD45.1). Cluster and IdU + cell frequencies were calculated using Cyt exported FCS files in FlowJo. For t-SNE plots overlaid with expression of individual parameters, signal intensity is displayed in arcsinh transformed values. For generation of heatmap displays, marker expression was normalized by dividing by the maximum cluster mean value for each parameter. Clusters of less than 0.5% frequency (of the input population; i.e., T cells) were not displayed in frequency plots or heatmaps to increase the clarity of the figures. This cutoff was conservative and was based on synthetic spike-in experiments using congenically labeled lymphocytes and murine TILs. A conservative cut-off was chosen because we preferred the risk of ''missing'' bona fide populations (i.e., false negatives) as compared to misidentification of populations (i.e., false positives); however we believe this approach is not conservative and enables robust classification. Notably, none of these low frequency populations were significantly modulated by checkpoint blockade treatment and the frequencies of other populations were not altered to reflect their omission from display. Therefore, this threshold for populations displayed does not alter any of the findings or affect the interpretations reached.
Manual gating frequencies were calculated in FlowJo with T reg and CD4 effector populations were defined as CD4 + FOXP3 + and CD4 + FOXP3 -, respectively. T cell subpopulations were defined using binary gating as shown in Figure S3 . The manually gated populations described in Table S2B were identified using only 14 parameters of the data (cisplatin 194 Pt , CD45, CD11b, CD3ε, CD4, CD8, FOXP3, TBET, EOMES, TIM3, ICOS, CD44, CD62L) . Correlations between the frequency of manually gated populations (traditional gating methods) and tumor volume were then assessed. As discussed in the main text, these findings indicate that subsets identified using PhenoGraph demonstrate much stronger correlations with tumor growth. Furthermore, these data suggest that high-dimensional profiling combined with unsupervised clustering is required to robustly detect these populations.
Principal component analysis of mass cytometry data
We applied principal component analysis in order to directly compare the phenotypes of T cell populations from different tumor models. EQ 4 bead normalized MC38 and B16BL6 tumor mass cytometry datasets were manually pre-gated for live CD45 et al., 2015) and cluster means were Z-transformed separately for each cohort (i.e., tumor model) to reduce batch effects. The Z-transformed cluster means were concatenated into a single matrix for principal component analysis. This approach enables direct comparison of multivariate T cell phenotypes across samples and between conditions (e.g., tumor type). Because of the inherent sparsity of high-dimensional spaces, multivariate phenotypes are more robust to technical variation (e.g., batch effects) than univariate phenotypes (i.e., individual marker intensities). Batch effect remains a potential confounding factor as these datasets were acquired independently, however it is noteworthy that no non-linear compensation is performed in analyses of mass cytometry data, thus reducing the potential for batch effects. This approach is therefore well suited to compare T cell populations across different technical batches. Furthermore, comparison of cluster means as opposed to single cells mitigates technical artifacts through averaging, while also importantly allowing the analysis to ignore differences in subset frequency.
To assess whether T cell phenotypes differed significantly between tumor models, the Kolmogorov-Smirnov test was used to assess the distributions of principal component scores for clusters stratified by tumor model. This resulted in 39 statistical tests, one test for each principal component; significance was assessed after using the Benjamini-Hochberg procedure to control false discovery at 5%.
Metaclustering of B16BL6 infiltrating T cells
Bead normalized mass cytometry data from three independent cohorts were manually pre-gated for live CD45 + CD11b -CD3ε + cells.
Prior to cluster analysis, in order to compress marker redundancies and reduce noise, data from each mouse were projected onto their principal component scores, truncated such that 99% of variance was preserved. Clusters were identified using PhenoGraph on a per mouse basis using all markers except CD45, CD3ε, IdU, and Live/Dead discrimination. PhenoGraph's parameter, k, was scaled to 0.2% of the number of cells (or at least 10). Individual-mouse clusters were allowed to merge across cohorts using a spectral clustering procedure. Cluster means were first Z-transformed for each cohort to reduce batch effects. This is particularly suitable to these data based the assumption that individual marker expression is stable within in-bred mouse lines implanted with the same syngeneic tumor cell line. An affinity matrix was constructed using the fixed-perplexity Gaussian kernel (van der Maaten and Hinton, 2008) . The perplexity and the number of clusters (43 and 14, respectively) were chosen simultaneously based on the location of the largest spectral gap over a wide range (10-50) of candidate perplexity values. The final number of clusters was defined by the location where the largest gap occurred most often and the final perplexity as the value which yielded the largest gap at this location. Thus, this procedure searches over the range of valid scale parameter values to identify the most commonly occurring location of spectral gap, which in turn identifies the number of clusters that is least dependent on the value of this scale parameter. Final cluster assignments were obtained by k-means with 500 random restarts on the k (14) first nontrivial eigenvectors of the Markov-normalized affinity matrix (perplexity = 43). The detection of T cell populations (i.e., metaclusters) with analogous phenotypes to corresponding subsets identified in single cohort analyses further supports the notion that an appropriate number of subsets were identified using this procedure. The effects of checkpoint blockade treatment on the association of metacluster frequency with tumor volume were tested using Kruskal-Wallis and Wilcoxon rank-sum tests. Correlation of tumor volume with metacluster frequency was assessed using Spearman's Rho and standard significance test.
Analysis of human melanoma mass cytometry datasets Data were bead normalized and debarcoded as described for murine mass cytometry datasets. For tumor samples for which multiple staining reactions (120 and 170), samples were first assessed for any intra-sample variation (between barcoded samples of the same sample) and then combined for downstream analyses. No intra-variation was observed between multiple barcoded samples. PhenoGraph clustering and t-SNE were performed (agnostic of CTLA-4, PD-1, Ki-67; see below) on a maximum of 40,000 cells down-sampled from each sample, and an arbitrary minimum of 1,000 cells. Our rationale for this was to protect against a low number of samples that had very high numbers of T cells compared to other samples from primarily driving clustering. Of note though, clustering was performed similarly using different down-sampling cutoffs (both higher and lower, down to 5,000 cells per sample) with similar findings. As in murine tumor datasets, a cut-off of 0.5% of total T cells was applied to this dataset. Based on this metric, five low frequency T cell subsets were not displayed in the heatmap or frequency plot. Notably, the phenotypes of these very low frequency populations suggested they were likely technical artifacts. Furthermore, the frequency of none of these populations was varied significantly between sample groups and the removal of these clusters from display did not affect the frequency of the remaining clusters displayed (i.e., other frequencies were not adjusted for their absence in the display). For t-SNE plots overlaid with expression of individual parameters and signal parameter histograms, signal intensity is displayed as arcsinh transformed values. For generation of the heatmap display, marker expression was normalized by dividing by the maximum cluster mean value for each parameter.
Previous studies have demonstrated that PD-1 receptor occupancy by anti-PD-1 antibody can persist for months following therapy, despite a serum half-life of 2 to 3 weeks of the antibody itself (Brahmer et al., 2010; Huang et al., 2017) . We did observe significant CTLA-4 and PD-1 signal despite samples being currently on therapy of anti-CTLA-4 and anti-PD-1 alone or in combination. However, to definitively exclude the possibility that checkpoint blockade treatments (Ipilimumab, Nivolumab, or Pembrolizumab) interfere with epitope recognition by CTLA-4 and PD-1 staining antibodies and thus cluster assignment, t-SNE analysis and PhenoGraph clustering were performed agnostic of CTLA-4 and PD-1. Ki-67 was also excluded from t-SNE analysis and clustering assignment to allow for assessment of proliferation within clusters as an independent variable, as similarly performed in murine tumor model experiments using IdU incorporation. CTLA-4 and PD-1 expression, in addition to Ki-67, were then assessed at independent variables for downstream analyses.
We also assessed whether there were any confounding signals in specific channels given that some metals used for mass cytometry detection are also utilized in clinical imaging (e.g., gadolinium as a contrast agent in magnetic resonance imaging). The effect of such imaging on mass cytometry outputs is unknown, however we find no compelling evidence that would be indicative of the presence of such background signal in the small number of surgically resected melanoma tumor samples analyzed. The one observed channel in which there was potentially non-biologically relevant signal (due to patient heterogeneity) was elevated levels of 140 Ce in one sample (patient sample 251). This was tolerable however given that the channel was not utilized for a biological parameter and the intensity was significantly lower than that of EQ 4 bead signal (10-100 fold less). Within this dataset there was appreciable acquisition-time dependent fluctuation in signal intensity of some channels (e.g., 89Y) even after bead normalization. Although samples within this analysis were barcoded and acquired together, we investigated whether such signal fluctuation affected cluster identification. PhenoGraph clustering was performed on a window of acquisition-time, representing approximately 30% of total cells, which displayed relatively low variance in signal intensity as a function of acquisition-time (data not shown). Results were highly similar to observations based on analysis of the complete dataset, both in terms of cluster phenotypes and frequencies thereof. Thus, the technical variation within this dataset does not appear to significantly affect the main observations and biological interpretation, at least in the context of robust cluster identification.
Analysis of RNaseq expression data
RNaseq data was aligned by TopHat2, using Ensembl GRCm38 as the reference genome. Gene read counts were generated using htseq-count. The bioconductor R package DESeq2 was used to normalize and analyze the RNA read counts matrix. Outliers were identified based on total read counts, normalized data distribution, principal component analysis (PCA), and hierarchical clustering, and omitted from downstream analyses. To identify genes with significant changes in expression, negative binomial generalized linear models (GLM) were constructed and likelihood ratio tests were used to identify overall treatment effects. Negative binomial GLM with Wald tests were used for pairwise comparisons of treatment groups. A Beta-Uniform Mixture (BUM) model was used to adjust for multiple comparisons (Pounds and Morris, 2003) . Two-way clustering, with Pearson distance metric and Ward's minimum variance method, was used to illustrate the expression profile of the identified genes. For Ingenuity pathway analysis (QIAGEN) an arbitrary cutoff of 1% false discovery rate (FDR) and minimum 2 fold change in gene expression were applied.
Whole-exome sequencing data analysis Whole-exome sequencing (WES) data was aligned using the Burrows-Wheeler Alignment Tool (BWA) using GRCm38 as the reference genome (Li and Durbin, 2009) . Picard was used to convert SAM files to BAM files, sort and mark duplicates. Bam files were then realigned and recalibrated using Genome Analysis Toolkit (GATK)(Van der Auwera et al., 2013) . The Mouse Genomes Project SNP and indel Release Version 5 were used as the known indels and SNPs for realignment and recalibration. These VCF files were downloaded from Sanger Institute FTP (ftp://ftp-mouse.sanger.ac.uk/REL-1505-SNPs_Indels/). VarScan2 was used to call the mutations without matched normal samples (Koboldt et al., 2012) . Data were annotated by ANNOVAR using NCBI Reference Sequence Database (Wang et al., 2010) .
Statistical Analyses
Statistical analyses were performed using Prism 6.0 (GraphPad) unless otherwise noted or described in previous method sections. Unpaired two-tailed t tests were used for tumor volume and CD8:Treg ratio comparisons. Linear regression analysis was used to determine correlations between cluster frequency and manually gated population frequency or spike-in percentage. Dunnett's multiple comparison tests were used for comparison of individual T cell cluster frequencies in treated (anti-CTLA-4 or anti-PD-1) groups versus that of the control group in murine immune checkpoint blockade tumor experiments. Tukey's multiple comparison tests were used to compare frequencies T cells derived from normal donor PBMC, ipilimumab treated (alone or in combination with nivolumab), and anti-PD-1 treated clinical samples.
DATA AND SOFTWARE AVAILABILITY
Mass cytometry datasets Bead normalized, debarcoded mass cytometry datasets as well as down-sampled, pre-gated data containing PhenoGraph and t-SNE coordinates as parameters are publicly available through Flow Repository. The mass cytometry data are available on a per experiment basis from Flow Repository (https://flowrepository.org) using the following Flow Repository experiment IDs: murine TIL spike-in data (FR-FCM-ZY66), MC38 checkpoint blockade data (FR-FCM-ZY69), B16BL6 checkpoint blockade data (FR-FCM-ZY6A), and checkpoint blockade treated human melanoma TIL data (FR-FCM-ZY6C).
RNaseq dataset
Processed RNaseq data is publicly available through GEO: GSE100807.
Whole-exome sequencing of murine cell lines Processed WES data is publicly available through GEO: GSE100808.
Metaclustering of mass cytometry data
Code implemented for the custom metaclustering procedure applied to B16BL6 mass cytometry data is available at https://github. com/jacoblevine/Wei_etal_Cell_2017. Table S2B . 
